Skip to main content
SpringerLink
Log in

HER2-positive Magen- oder AEG-Adenokarzinome

Pembrolizumab plus Trastuzumab und Chemotherapie

  • Journal club
  • Published:
Gastro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Ilson DH. Clin Adv Hematol Oncol. 2021;19(10):639-47

  2. Bang YJ et al. Lancet. 2010;376(9742):687-97

  3. Janjigian YY et al. Nature. 2021;600(7890):727-30

  4. Rha SY et al. Lancet Oncol. 2023;24(11):1181-95

  5. Kwok G et al. Hum Vaccin Immunother. 2016;12(11):2777-9

  6. Yoon HH et al. JAMA Oncol. 2022;8(10):1456-65

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Hugstetter Straße 55, 79016, Freiburg, Germany

    Fabienne Horr Ärztin &  Michael Quante

Authors
  1. Fabienne Horr Ärztin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Quante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabienne Horr Ärztin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horr, F., Quante, M. Pembrolizumab plus Trastuzumab und Chemotherapie. Gastro-News 11, 12–14 (2024). https://doi.org/10.1007/s15036-024-3660-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-024-3660-5

Search

Navigation